| Size | Price | |
|---|---|---|
| 50mg | ||
| 100mg | ||
| 250mg |
| ln Vitro |
Imipramine (0.5-300 μM, 3 days) reduces the viability of HCT-116 cells [1]. Cell invasion (48 hours) and migration (7.5 hours) are inhibited by imipramine (20 μM) [1]. In U-87MG glioma cells, imipramine (50 μM, 0-240 min) suppresses the PI3K/Akt/mTOR signaling pathway [2]. In U-87MG glioma cells, imipramine (60 μM, 24 hours) promotes autophagy [2]. In HL-60 cells, imipramine (80 μM, 24 hours) causes apoptosis [3].
|
|---|---|
| ln Vivo |
Imipramine reverses stress-induced social avoidance in rats and attenuates neuroinflammatory signaling when administered intraperitoneally (20 mg/kg orally; taken once daily for 24 days) [4].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: DLD-1, HCT-116 and SW-480 Tested Concentrations: 0.5-300 μM Incubation Duration: 3 days Experimental Results: Inhibition of cell viability, HCT-116 is more sensitive than DLD-1 and SW-480 . Cell migration assay[1] Cell Types: DLD-1, HCT-116 and SW-480 Tested Concentrations: 20 μM Incubation Duration: 7 hrs (hours) Experimental Results: Significant migration inhibition was produced in all cell lines tested. Cell invasion experiment [1] Cell Types: HCT-116 Tested Concentrations: 20 μM Incubation Duration: 48 h Experimental Results: Matrigel inhibits cell invasion. Western Blot Analysis[2] Cell Types: U-87MG Tested Concentrations: 50 μM Incubation Duration: 0, 15, 30, 60, 120 and 240 minutes Experimental Results: Significant time-dependent inhibition of phosphorylation of Akt (Ser473) and mTOR (Ser2481) The way. Also dephosphorylates p70 S6K, a downstream target of mTOR. Autophagy assay [2] Cell Types: U-87MG Tested Concentrations: 60 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of autophagy is stimulated by redistribution of LC3 in U-87MG glioma cells. Apoptosis a |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice (6-8 weeks old) were subjected to RSD (repeated social defeat) and HCC (home cage control) [4]
Doses: 20 mg/kg or 15 mg/kg Route of Administration: intraperitoneal (ip) injection or administered orally daily for 24 days. Experimental Results: Reversed RSD-induced social avoidance behavior, Dramatically increased interaction time, and Dramatically diminished stress-induced IL-6 mRNA levels in brain microglia. |
| References |
[1]. Alburquerque-González B, et al. New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells. Exp Mol Med. 2020 Feb;52(2):281-292.
[2]. Jeon SH, et al. The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun. 2011 Sep 23;413(2):311-7. [3]. Xia Z, et al. The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. [4]. Ramirez K, et al. Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav Immun. 2015 May;46:212-20. [5]. Balkovetz DF, et al. Evidence for an imipramine-sensitive serotonin transporter in human placental brush-border membranes. J Biol Chem. 1989 Feb 5;264(4):2195-8. |
| Molecular Formula |
C19H24N2
|
|---|---|
| Molecular Weight |
280.41
|
| Exact Mass |
280.1939
|
| CAS # |
50-49-7
|
| Related CAS # |
Imipramine hydrochloride;113-52-0;Imipramine-d6;65100-45-0;Imipramine-d4;96705-18-9
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
|
| Synonyms |
NSC 169866 NSC-169866Imipramine Tofranil Dyna-zina Dimipressin EINECS 200-042-1 HSDB 3100 NSC169866 PryleuganHSDB3100 HSDB-3100 Melipramine BRN 0256892 BRN-0256892 BRN0256892
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5662 mL | 17.8310 mL | 35.6621 mL | |
| 5 mM | 0.7132 mL | 3.5662 mL | 7.1324 mL | |
| 10 mM | 0.3566 mL | 1.7831 mL | 3.5662 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
